BioSpace News Archive

Roche Diagnostics, a division of Hoffmann-La Roche Limited, is proud to announce Health Canada approval for its Cerebrospinal Fluid (CSF) assays* to measure three biomarkers that are hallmarks of Alzheimer’s pathology, beta-amyloid and tau proteins, in adults aged 55 and older being evaluated for the disease.

Indica Labs today announces the launch of a service offering deployment and on-going support of its HALO ® digital pathology software in a fully managed cloud-hosted environment powered by Amazon Web Services (AWS).

Sparrow Pharmaceuticals will present the rationale that its lead candidate and HSD-1 inhibitor, SPI-62, is predicted to be associated with limited adrenal insufficiency risk in Cushing’s syndrome during a poster session at the Endocrine Society (ENDO) 2023 Annual Conference. The meeting will be held in-person from June 15-18, 2023 in Chicago, IL.

Sionna Therapeutics today announced the presentation of preclinical data demonstrating the activity of the company’s portfolio of compounds targeting the first nucleotide-binding domain (NBD1) of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

Agilent Technologies Inc. (NYSE: A) today announced the release of the Agilent BioTek 406 FX washer dispenser, a compact instrument that combines multifunctional reagent dispensing and plate-washing capabilities.

Parse Biosciences announced today the launch of CRISPR Detect, enabling single cell pooled CRISPR screens at unprecedented scale.

Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, today announced that the U.S. Food and Drug Administration (FDA) cleared the company to initiate its Phase 1 clinical trial of PIPE-791 in healthy volunteers.

Techdow USA Announces Launch of its Generic Lovenox ® , (Enoxaparin Sodium – Preservative Free) in Prefilled Syringes.

Bayer, one of the country’s leading life-sciences companies, announced changes to its U.S. Country Leadership Team.

Oxford Biomedica Solutions LLC, offers The Full Solution™ suite of services, which includes end-to-end development and manufacturing capabilities for cell and gene therapy.